Pharma

Trump's Price Deals With Nine Drug Makers Expose How Government Meddling Distorts Markets

Eli Lilly Drops $2.88 Billion on Merida to Escape the Weight-Loss Trap

NurExone: Canadian Biotech Bets on US Production and Mexican Distribution

Lilly Swings $2.88 Billion at Merida to Own Autoimmune Next

Defence Therapeutics Bets on Alpha and Beta Emitters – Accum® Set to Revolutionize Radiopharmaceuticals

Hair-Loss Boom Lures Capital as Regulators Lag

Bayer: Finerenon Slows Kidney Failure in Hypertensive Patients – A Market Politics Should Not Overregulate

Hair-Loss Drug Stocks Soar as Wall Street’s Next Big Bet After GLP-1 Boom

Electra Files for IPO to Fund Immune and Cancer Pipeline

BioNTech Halts Colorectal Cancer Trial – 10% Stock Plunge in New York

Lilly's Mounjaro Wins Heart-Disease Approval, Expanding the GLP-1 Battlefield

India’s Cheap Weight-Loss Drugs Hit Cultural Wall Despite $14 Price

CanSino CEO Lays Out Pipeline Reality Check After First-Half Numbers

Revolution Medicines Scores $475K Breakthrough Against Pancreatic Cancer

Novo Nordisk Downgraded to Sell as Ozempic Glow Fades

Ebola Vaccine Race Expands as Congo Bundibugyo Outbreak Grows

Trump White House Drug-Price Deals Signal Market Over Bureaucracy

Roche Secures FDA Approval for HER2 Tests in Esophageal Cancer

Revolution Medicines Scores First-in-Class Win: Daraxonrasib Approved for Pancreatic Cancer

Faron Advances Cancer Trial While Hunting Capital Partners

BioNxt Solutions: Cladribin Film Achieves Critical Regulatory Milestone for MS Patients

Moderna’s mRNA Cancer Vaccine Clears First Major Hurdle — Merck Partnership Pays Off

Moderna-Merck mRNA Vaccine Cracks Cancer’s Code, Delivering Real Returns

NurExone Raises $1.07M CAD – Exosome Biotech Prioritizes Operational Independence Over Government Subsidies

Moderna’s mRNA melanoma vaccine is promising, but investors should demand real data before bidding it up

GLP-1 Drugs Are Turning Teens Into Lab Rats for Pharma and the State

Moderna Stock Explodes After Cancer Vaccine Success — The Market Proves What’s Possible When the State Doesn’t Interfere

Moderna’s Cancer-Vaccine Breakthrough Ignites a Biopharma Rally—Time to Ditch the Regulators Who’ve Slowed the Whole Sector

Moderna-Merck mRNA Vaccine Crushes Melanoma Recurrence, Proving Regulators Are the Real Bottleneck

Moderna-Merck mRNA Shot Crushes Melanoma Recurrence — Regulators Should Get Out of the Way